TWO · 4170.TWO
Vectorite Biomedical Inc.
NT$12.00NT$0.00 (0.0%)
Vectorite Biomedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.88% below the high.
Loading market information…
TWO · 7607.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 06:12 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
DuoGenic StemCells corporation’s quoted price sits in the lower half of its reported 52-week range, 45.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Duogenic Stemcells Corporation is primarily engaged in the biotechnology and healthcare industries, offering a variety of services. Their core offerings include cell therapy and the development of closed-culture cell systems. The company was established on March 22, 2018, and its main corporate office is situated in Taichung, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$12.00NT$0.00 (0.0%)
Vectorite Biomedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.88% below the high.
NT$9.72+NT$0.15 (+1.57%)
Health & Life Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.97% below the high.
NT$12.60+NT$0.15 (+1.2%)
UniPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.25% below the high.
NT$6.97-NT$0.23 (-3.19%)
Sunder Biomedical Tech. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.4% below the high.
NT$29.90-NT$0.60 (-1.97%)
A-SPINE Asia Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.17% below the high.
NT$7.78+NT$0.33 (+4.43%)
Pharmigene, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.35% below the high.
NT$16.60-NT$0.60 (-3.49%)
Welgene Biotech Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.43% below the high.
NT$14.40+NT$0.35 (+2.49%)
EPS Bio Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 22.16% below the high.
